By Ben Butkus
A new study provides further support for MDxHealth's PredictMDx brain cancer test, which predicts which patients will respond to the alkylating chemotherapy temozolomide.
Asuragen said that that in the second half of this year it will release research-use-only reagents for evaluating FMR1 methylation status in the hopes of obtaining independent validation of the technology.
Exact has been evaluating several MDxHealth methylation biomarkers, among other biomarkers, as well as its methylation-specific PCR technology, under a previous licensing agreement.
The US National Institutes of Health's All of Us project awarded $4.6 million to the company Color to develop a genetic counseling resource for the program.
The Times of India reports on a pilot study that used genomic testing to determine whether patients had drug-resistant tuberculosis.
New guidelines say that more women may benefit from genetic testing for hereditary breast or ovarian cancer, according to the Los Angeles Times.
In Cell this week: small proteins identified among human microbiome, role for tumor microbes in pancreatic cancer survival, and more.